EFFECTIVENESS AND SAFETY OF NIRMATRELVIR/RITONAVIR IN REAL LIFE SETTING


PHARMACY, HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLES, ZARAGOZA, SPAIN.

BACKGROUND

On March 28th 2022, nirmatrelvir/ritonavir was marketed in Spain. The Spanish Agency for Medicines and Medical Devices (AEMPS) established criteria to prioritize its administration in patients at high risk of progression to severe COVID.

PURPOSE

To assess the effectiveness and safety of nirmatrelvir/ritonavir in patients at high risk for severe COVID-19

MATERIAL AND METHODS

Prospective descriptive study from April to August 2022 of patients treated with nirmatrelvir/ritonavir. Sociodemographic variables, vaccination status, hospital admission, high risk factors for progression and concomitant treatment were recorded. Readmissions were recorded within 30 days of the end of antiviral treatment.

RESULTS

Characteristics of study patients. (n=53)

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age</td>
<td>64 years</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
</tr>
<tr>
<td>women</td>
<td>51%</td>
</tr>
<tr>
<td>men</td>
<td>49%</td>
</tr>
<tr>
<td>Mean number of days from onset of symptoms</td>
<td>1.6</td>
</tr>
</tbody>
</table>

High-risk criteria

- Treatment with myelotoxic chemotherapy: 24%
- Treatment in the previous 6 months with anti-CD20 drugs: 21%
- Patients over 80 years vaccinated with some risk factor for progression: 14%
- Patients with oncohematological treatment: 7%
- Treatment in the previous 3 months with inhibitors of the proteinkinase: 7%
- Persistent covid (off label): 6%
- Others: 21%

VACCINATION

- No vaccinated: 11%
- 1 dose: 6%
- 2 doses: 17%
- 3 doses: 57%
- 4 doses: 9%

DOSE ADJUSTMENT DUE TO RENAL IMPAIRMENT

- Adjusted dose: 23%
- Standard dose: 77%

PATIENTS WITH ADJUSTMENT OF CHRONIC TREATMENT FOR INTERACTIONS

- No interactions: 47%
- Interactions: 53%

CONCLUSIONS

Nirmatrelvir ritonavir has been shown to be a safe and effective drug in high-risk patients of progression to severe covid.